(NASDAQ: ARQT) Arcutis Biotherapeutics's forecast annual revenue growth rate of 28.34% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 83.67%, and while it is forecast to beat the US market's average forecast revenue growth rate of 10.8%.
Arcutis Biotherapeutics's revenue in 2025 is $263,465,000.On average, 3 Wall Street analysts forecast ARQT's revenue for 2025 to be $39,550,330,263, with the lowest ARQT revenue forecast at $38,849,245,272, and the highest ARQT revenue forecast at $40,695,903,378. On average, 3 Wall Street analysts forecast ARQT's revenue for 2026 to be $51,646,354,532, with the lowest ARQT revenue forecast at $50,609,655,227, and the highest ARQT revenue forecast at $52,758,234,320.
In 2027, ARQT is forecast to generate $67,380,778,487 in revenue, with the lowest revenue forecast at $61,489,122,575 and the highest revenue forecast at $73,626,514,095.